Speaker Biographies

Sultan Aziz, Senior Director, Product Supply Strategy Deployment, Johnson & Johnson

Sultan is responsible for providing overall leadership and direction to the Capacity Management department within the PMO. His responsibilities include capacity and demand analyses, operational risk analysis and scenario modeling in support of the Janssen R&D Book-of-Work development pipeline and associated business processes. Sultan joined JnJ from Merck & Co., where he held key positions of increasing responsibility in R&D Business Operations, Project Management, R&D and Manufacturing Finance. His broad background includes basic research drug discovery and development, launch of several successful products, licensing and acquisitions as well as Over-the-Counter Rx to OTC switches. Sultan holds a MBS in Finance and BA in Biology.

Greg Bayer, Head of Strategy & Operations, R&D Business Insights & Analytics, Bristol-Myers Squibb

Greg Bayer leads the R&D Scheduling and Resource Management function in R&D Operations, which is responsible for drug project scheduling, resource & capacity planning and enabling pipeline planning and operations in various settings, including the R&D budget process, the study start approval process, GDOC operations, and others. Prior to his current role, Greg was Director of Global Business Operations in Global Medical, in which he led the annual medical planning process. He joined BMS from the Health & Life Sciences strategy practice at Accenture, where he worked with pharmaceutical industry clients in the areas of R&D governance, resource management, brand strategy, sales acceleration and shareholder value creation. Prior to business school, he worked in a molecular biology research position and as a project manager at a CRO. Greg holds a Bachelor’s degree in Biology from Wake Forest University and an MBA from the Kenan-Flagler Business School at UNC-Chapel Hill.

 Richard Bayney, Ph.D., President & Founder, Project & Portfolio Value Creation (PPVC)

Dr. Richard Bayney is President & Founder of Project & Portfolio Value Creation, a consulting boutique providing training and education in project, program, portfolio, resource, and risk management as well as client services in strategic, business, and portfolio planning. He is an adjunct faculty member at the University of Pennsylvania. Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. He obtained his M.Sc. and Ph.D. from University of London, MBA from Columbia University, and PMP from the Project Management Institute. In his last corporate position, Dr. Bayney was Head of Decision Analysis & Portfolio Management at Johnson & Johnson Pharmaceutical Research & Development.

Elizabeth Claire Bearby, Pharm.D., Senior Director, R&D, Project Management, Eli Lilly and Company

Elizabeth Bearby, PharmD, has worked at Eli Lilly and Company for over 21 years. She has her Doctor of Pharmacy from Purdue University and is currently the Senior Director for Early Phase Project Management. In this role, she has responsibility to drive and enhance portfolio decision processes and outcomes in addition to managing a staff of program team leaders. Prior to this role, Elizabeth spent over 19 years of industry experience in Regulatory Affairs. Elizabeth’s experience includes extensive early phase and late stage product development, NDA/BLA product registration, external and internal policy development, biosimilar development, and product life cycle management.

Robert Boland, MBA, Associate Director, Emerging Science and Innovation Strategy, Johnson & Johnson

Robert J, Boland, MBA is currently Associate Director of Emerging Science and Innovation Strategy at Johnson & Johnson Consumer Companies. In this role Robert is responsible for driving Strategy and Operations for Emerging Science and Innovation (ESI) initiatives, leading External & Open Innovation, Opportunity Assessment & Scouting, and key Strategic operational initiatives while managing the ESI portfolio and measuring value creation for the Emerging Science and Innovation (ESI) function of Johnson & Johnson Consumer R&D. Additionally, Robert is responsible for driving the cultivation of a “culture of innovation” and cutting-edge research across the Consumer R&D organization and in developing an upstream portfolio of early science that will help ensure the long-term sustainability and growth of the Johnson & Johnson Consumer business. Responsibilities also encompass driving OI strategic partnerships, Crowdsourcing and key decision-making and execution of the ESI strategy along with business model innovation, business analytics, intelligence and bench-marking and value creation metrics; driving development of collaborative open innovation models, incubators/accelerators, catalyzers, and leading ESI communication initiatives, both internally and externally, and manage a new Scientific Advisory Board of internal and external key opinion leaders and experts. Robert is also leading and managing contracting and agreement-forming activities with external partners and navigation of the healthcare compliance approval process and serves as the primary point of contact for interactions with other Consumer functions (e.g., R&D Leadership Team, Franchise R&D and Platform Leads, Finance, Regulatory, Legal and External/Open Innovation) as well as with cross-sector functions/teams from Pharma R&D, and Medical Device and Diagnostics.

Erin Brubaker, Vice President, R&D Strategy Development and Deployment, GlaxoSmithKline

As the Vice President of R&D Strategy Development and Deployment at GlaxoSmithKline (GSK), Erin leads a global team to develop, implement and embed the strategies that will enable GSK to sustain and grow its leadership position in the field of medicines discovery and development. In this role, she leverages her previous success in driving alignment across multiple diverse groups and stakeholders, her external focus and past experience in the R&D/Commercial interface, to contribute to the development of the enterprise-level R&D agenda and strategic direction. Her unique career path has allowed her to develop a rare skill set of being ‘bilingual’ in both Commercial and R&D. Among her professional accomplishments, she is most proud of being named a ‘Rising Star’ by the Healthcare Businesswomen’s Association and for serving as an Executive Coach and Mentor to colleagues in the Life Sciences industry.

 Amy Davis, Senior Director Pharmaceutical Project Management, Medicines Development Unit, Eli Lilly and Company

Amy Davis, RPh, is a Senior Director in Pharmaceutical Project Management for Eli Lilly and Company. She is a Pharmacy graduate of Purdue University and practiced in a retail pharmacy setting prior to her 18-year career in the pharmaceutical industry. During her time at Eli Lilly, Amy has held numerous leadership positions that span therapeutic areas supporting clinical and integrated drug development, medical affairs, strategy and operations, and project/portfolio management. In her current assignment, she has accountability for the pharmaceutical project management organization; the development and continuous improvement of project management capabilities and portfolio systems; the resource modeling and forecasting capabilities as well as overseeing enhancements to Lilly’s submission and approval processes. Amy and her husband, Chris have two children. In her time outside of work, she enjoys cooking, reading, running, and spending time with her family and friends.

Gill Eapen, Managing Director, Predictive Economics, Stout Risius Ross (SRR)

Gill Eapen is the founder and chairman of Decision Options ® and the Managing Director of the Predictive Economics practice at Stout. Mr. Eapen has over 30 years of experience in strategy, finance, engineering, risk and general management. Over the past two decades, Decision Options pioneered advanced analytical techniques to inform and guide decisions to enhance shareholder value in companies of all sizes. Mr. Eapen is the author of two text-books. The first book, Decision Options: The Art and Science of Making Decisions, provides the theory and practice of real options in economic valuation and investment decision-making in private assets. The second book, Flexibility: Flexible Companies for the Uncertain World is a comprehensive discussion of the structure, systems and strategies needed for companies to survive and succeed in an increasingly uncertain world.

Jared Fantasia, Head, Global NPD Portfolio Operations, Johnson & Johnson

Jared Fantasia is currently the Head of Global NPD Portfolio Operations at Johnson & Johnson in their Consumer Products Sector. His entire professional career has been spent within the Johnson & Johnson family of companies where he started in the Pharmaceutical sector in upstream R&D Research, then transitioned to Product Development and Clinical Testing of Consumer products and over the last 6 years has been part of the Global Portfolio organization. In his current role, Jared and his team of portfolio analysts have direct responsibility for managing the operations of the project portfolio systems for Consumer J&J globally, training and process improvement of the New Product Development Stage-Gating process, facilitating decision analysis at global cross-business unit governance, and multiple levels of Portfolio analytics reporting.

Sam Gabrielli, Associate Director, Portfolio & Project Management, Gilead Sciences

Sam is currently an Associate Director in Research & Development, Project and Portfolio Management at Gilead Sciences and is responsible for Strategic Resource Management and the development and implementation of integrated PPM processes, systems and tools. Sam has 18 years’ experience in Bio-Pharma at Gilead Sciences, Roche & Genentech. He holds a BS from University of California Davis, MBA from University of Colorado, and PMP from PMI.

Keith Gardner, Senior Director, Decision Science, AstraZeneca

Keith Gardner is the Senior Director and founder of the Decision Science Practice at AstraZeneca. He came to AZ after a long career in Defense and the Intelligence community. His background is in Mathematics, Operations Research and Decision Analysis. He and his team have been delivering results using decision trees, multi-criteria choice, recruitment modeling, facilitation and strategic planning.

Heather Gaylord, Associate Director & Lead, Program and Change Management, Shire

Biography coming…

Amy Hargis Peltz, Senior Director, LRL Project Management, Research & Development, Eli Lilly and Company

Biography coming…

 Lauren Hirshon, Lecturer, The Wharton School of the University of Pennsylvania; Director of Operations and Development, Leadership for a Networked World, Harvard University

Lauren Hirshon is an organizational change and transformation consultant for businesses, governments, and nonprofits. Curious by nature, she has a broad set of interests and areas of expertise, including: organizational development, change management, group and team dynamics, and working across organizational boundaries. She is currently the Director of Operations and Development for an applied research and advisory program at Harvard and a Lecturer and Consultant with the Wharton school. Lauren received her B.A. from Harvard College in Psychology with a minor in French, and her Master’s Degree in Organizational Dynamics from the University of Pennsylvania. Outside of the office, Lauren serves as the Secretary for the Harvard Club of Philadelphia and plays on touch football, basketball and softball teams. And don’t mess with her – she’s a wicked shot with the javelin.

Jo James, Associate Director, Resource & Performance Management, R&D Business Operations, Biogen

With over two decades of experience in Clinical Development, Jo is part of Biogen's R&D Business Operations team, focused on program and resource management. Her current responsibilities include driving the processes to ensure the organization can plan and forecast activities and resources to execute their portfolio and ensure that the tools being used are able to provide information for data-driven decisions. In doing this Jo collaborates with stakeholders and end-users across all departments of R&D to ensure consistency and efficiency.

Josh Kaminetz, Resource Management Lead, Global Regulatory Affairs and Clinical Safety, Merck & Co.

Josh Kaminetz is Resource Management lead in the Business Operations and Strategy group of Merck’s Global Regulatory Affairs and Clinical Safety subdivision. His small team enables GRACS leadership to make informed business decisions by providing capacity and demand forecasts. Josh has a 25-year professional career in the pharmaceutical industry. After earning a Bachelor’s of Science degree in Chemistry from the University of Richmond, he spent the first half of his career as a bioanalytical chemist and laboratory manager for a CRO in Richmond, Virginia. Shortly after achieving a Master’s of Business Administration degree at Virginia Commonwealth University, he joined Merck Research Laboratories in Upper Gwynedd, PA, where he held operations management roles supporting a variety of Discovery and Early Development leaders for a decade- until moving into his current role as Resource Management lead within Global Regulatory Affairs and Clinical Safety

Elayne Ko, Director, Portfolio & Decision Analysis, Pfizer

Elayne Ko currently holds a Director position at the Portfolio and Decision Analysis (PDA) group within Pfizer, Inc. She has over 15 years of experience in applying decision analysis to investment decision-making under uncertainties. Her focus is primarily within the pharmaceutical industry; in particular, drug research and development (R&D) decisions, long-term planning, and disease area/portfolio prioritization. She works with R&D teams and senior management making funding decisions. Elayne has worked – in the consulting and corporate settings – across several industries including healthcare information technology, oil & gas and mining. Prior to Pfizer, Elayne held positions as Portfolio Manager at Siemens Health Services Strategy Group, Manager at Deloitte Financial Advisory Services LLP, and Senior Consultant within the Applied Decision Analysis (ADA) group of PricewaterhouseCoopers (PwC). Elayne obtained a BSc in Management Sciences and MSc in Decision Sciences from The London School of Economics; and she is a Board member of the Society of Decision Professionals (SDP).

Delfi Krishna, Ph.D., Director of Operations, Planning and Strategy, Cell and Gene Therapy Platform, GlaxoSmithKline

Delfi Krishna has a Ph.D. in Chemical and Biomolecular Engineering, with a specialization in Cell and Gene Therapy. She is currently the Director of Operations, Planning and Strategy for Cell and Gene Therapy Platform R&D at GlaxoSmithKline. She is accountable for 3-5 year strategy development and deployment, streamlining operations and developing solutions for recruitment, engagement, training and development. Assessing performance, enabling senior leader decision making etc. Previously roles include Biopharmaceutical Portfolio Strategy and Operations, Supply Chain Strategy, Matrix Project Leadership.

Nate Lewis, Senior Advisor, Project Management for Research and Development, Eli Lilly and Company

Nate Lewis is the Senior Advisor of Project Management for Research and Development at Eli Lilly and Company. His responsibilities include leadership of the R&D project leaders for development assets, leading portfolio governance, and providing program management for special corporate initiatives related to portfolio management and delivery. Prior to his current role, Nate was a project leader and program leader for both early- and late-phase assets across multiple therapeutic areas and commercial opportunities. His experience includes leading internally developed and partnered/outsourced projects. He was also the program leader for the implementation of the Corporate Integrity Agreement and for special initiatives related to development cycle time improvement and cost reduction. He has worked in the drug development space for the past 20 years. Prior to that, he was a project leader for both capital delivery and process optimization projects for 10 years with Eli Lilly and Company.

Nate is a registered professional engineer and certified Project Management Professional. He has previously served as Vice President for the PMI – Central Indiana Chapter and has been active with PMI National initiatives. He also has served on the board of a number of not-for-profit organizations. He currently serves as Vice Chairman of Elements Financial Credit Union.

Sam Mathew, MBA, R&D Analytics Leader, Project Portfolio Management, Janssen, Pharmaceutical Companies of Johnson & Johnson

Sam Mathew, MBA, PMP, Lean Six Sigma Black Belt, Stanford Certified Advanced PM R&D Analytics Leader, Project Portfolio Management Janssen, Pharmaceutical Companies of Johnson & Johnson Sam Mathew is a senior leader in Pharmaceutical industry and Management Consulting, with a passion for Strategic Planning, Business Analytics, Organization/People Development, and Transformational Change. Sam is currently the Leader for R&D Analytics at Janssen. At Janssen, Sam has also lead the Capacity Management team. Prior to joining Janssen, he has held positions of increasing responsibility at Merck & Co., Accenture, PepsiCo and Apple. He brings over 22 years’ experience in Pharmaceutical Research & Development, Management Consulting, Project/Portfolio Management, Supply Chain, Process and Information Management, Data Sciences and Business Analytics. Sam holds a M.B.A. from Texas Christian University and BS in Physics and Mathematics. Sam is a certified PMP, Lean Six Sigma Black Belt, and Stanford University Certified Advanced Project Management.

 Derek Newberry, Ph.D., Business Anthropologist; Affiliated Faculty in Organizational Dynamics, The Wharton School of the University of Pennsylvania; Author “Committed Teams”

Derek Newberry is Affiliated Faculty in Organizational Dynamics at the University of Pennsylvania. He also teaches in the Wharton School’s Executive Education program on interpersonal communication, collaboration, and corporate culture. As a consultant, he advises senior leaders in Fortune 500 companies and major non-profits on the human factors that drive organizational effectiveness. Derek has worked with organizations in a wide range of sectors, including energy, financial services, management consulting, and healthcare. Derek is the co-author (with Mario Moussa and Madeline Boyer) of Committed Teams: Three Steps to Inspiring Passion and Performance (Wiley Press, 2016); a practical, research-based guide for getting the most out of groups. His work has been featured in Forbes, Quartz, and leading industry publications. He is a contributor for Fortune.com and Entrepreneur.com. He designed and launched a series of Coursera courses on building high-performing teams with University of Pennsylvania colleagues that have been taken by thousands of learners. Derek has published extensively and lectured internationally on cultural barriers to organizational change, including speaking engagements at the World Bank, Copenhagen Business School, Stanford University, and the University of São Paulo, among others. Derek received his Ph.D. in Cultural Anthropology from the University of Pennsylvania, where he won a National Science Foundation grant to support his research on barriers to change in the Brazilian energy industry.

Sean Pales, CEO, Tempus Resource by ProSymmetry

Sean Pales is the CEO of ProSymmetry and has a degree from Columbia University, MS Engineering from the University of Pennsylvania and an MBA from The Wharton School of Business. His years working at Microsoft and the founding of ProSymmetry has allowed him to work with over 500 companies and their resource and portfolio management requirements.

Daniel Patrick, Senior Consultant, TayganPoint Consulting Group

A Senior Management Consultant at the TayganPoint Consulting Group, Daniel Patrick has more than 25 years of combined experience in the Life Sciences and Financial Services industries. His areas of expertise include program and project management, R&D, merger & acquisition planning and integration, business process reengineering, and strategy development and implementation. In the life sciences space, he has worked at both Merck and Celgene, holding positions of increasing responsibility in Financial Evaluation & Analysis, Divisional Financial Services, Treasury, Corporate Operational Excellence, and R&D.

 Matthew Pazdernik, Director, Submission Planning and Portfolio Management Lead, Regulatory Affairs, Merck & Co.

Matt Pazdernik is a Director of Regulatory Affairs within the Global Regulatory Operations and Quality Management organization at Merck. He leads the Submission Planning and Portfolio Management team; in this role he has led the design and development and begun implementation of the Portfolio and Submission Project Management (PSPM) tool and process, which enables best-in-class regulatory submission project management and visibility into the entire portfolio of regulatory submission work. Matt has held several roles at Merck supporting business operations and strategy in a variety of functions, including Global Project Management, Learning and Development, and Business Integration. Prior to joining Merck in 2006, Matt worked in Supply Chain Analysis for the Kimberly-Clark Corporation. Matt has a B.S. in Business Administration from Oglethorpe University, and a Masters of Business Administration with concentration in Strategy, Operations, and Global Business from the Leonard N. Stern School of Business - New York University. Matt is also a certified Project Management Professional (PMP) and Six Sigma Black Belt.

Ian Popoff, Senior Director, Strategic Portfolio Management, Pfizer

Ian is currently in role as Senior Director, Strategy & Portfolio Management (SPINE), and has over 15 years of Pharmaceutical Industry experience. He has authored nine publications in scientific journals including Nature, Diabetes & PNAS, and has eight issued patents (several pending). Ian began his career in science at the laboratory bench, discovering new treatments for cancer and diabetes, based on the emerging scientific literature and rational drug design. After taking an opportunity to move into the Project Management field, he has led projects, built and managed teams, and provided senior leaders with objective risk assessments to enable decision making. Ian leveraged his MBA into a skip level promotion, and began to provide Portfolio Strategy, Analytics, and Management guidance to senior executive leadership. His current role within Research & Development aims to marry sound business judgment with cutting edge science, to provide Pfizer with the best options for drug development investments. Ian graduated from the University of Calgary, Canada with a Master of Science in the Faculty of Medicine, department of Biochemistry and Molecular Biology, and earned an executive MBA from the University of California, Irvine (Beta Gamma Sigma Award, Dean's Scholar).

 Aaron Salancy, MBA, Director, Strategic Options & Assessment, Bristol-Myers Squibb

Aaron Salancy is the Director of Oncology Asset Strategy in Bristol-Myers Squibb’s Strategic & Operational Portfolio Management group. The team of analysts he leads is responsible for the evaluation of internal asset development strategies, helping matrix development teams identify the optimal path to initial registration and the sequencing and scope of life cycle management activities. Aaron partners with oncology leaders in discovery, R&D, medical, commercial, and regulatory roles to develop oncology asset and portfolio strategy. Aaron has previously held similar roles at BMS with responsibility for the cardiovascular, metabolics, neuroscience, virology, and immunoscience therapeutic areas. Prior to joining BMS, Aaron worked in decision analysis at Pfizer, heading the Portfolio Valuation and Prioritization group, with responsibility for valuing and prioritizing the development portfolio within budget constraints, after leading decision analysis support for several therapeutic areas. Aaron holds a BS in Naval Architecture from Webb Institute, a Master of Engineering in Naval Architecture from UC Berkeley, and an MBA from the Kellogg School of Management at Northwestern University.

Kelly Schmidt, Senior Director and Head, R&D Analytics, Project Management Organization, Janssen Research & Development

Kelly Schmidt is the Senior Director & Head of R&D Analytics within the Janssen R&D Project Management Office. She provides overall leadership to an analytical team in support of project, portfolio and capacity management of the Johnson & Johnson Pharmaceutical R&D pipeline. Through creative use of color, design and story-telling, Kelly’s team is focused on creating insights that lead to action for the PMO. Prior to joining the JRD PMO in 2015, Kelly spent 15 years in IT across multiple sectors of Johnson & Johnson focused on business intelligence, analytics, and portfolio management. Throughout her career, Kelly has been passionate advocate for mentoring, talent development, and organizational change. She holds a Master’s in Information Systems and a dual Bachelor’s in Mathematics & Computer Science.

Kathrin Schoenborn-Sobolewski, Ph.D., Vice President, Integrated Planning, Analytics & Partnering, Merck KGaA, Darmstadt, Germany

Kathrin Schoenborn-Sobolewski, PhD, is VP, Integrated Planning, Analytics & Partnering at Merck KGaA, Darmstadt, Germany. In this role, she leads the R&D wide implementation of a new integrated Business Operations approach and solution as well as the R&D wide sourcing and vendor management approach. Kathrin is a pharmacist and holds a PhD from the University of Bonn, Germany. After several years in public pharmacies and with SANDOZ, she joined Merck KGaA, Darmstadt, Germany in October 1995. Overall, Kathrin has more than 25 years of global healthcare experience in Project Leadership, Business Development, Commercial, Strategic Innovation, Change Management and Global Clinical Operations. She is recognized as an inspiring leader with a proven track record of success in building and leading high performing teams, designing and implementing change and driving delivery and results. Kathrin is also passionate about diversity in business, as an active volunteer and board member with the Healthcare Businesswomen’s Association (HBA) European Chapter. In 2015, she was honored as HBA Luminary as a role model, active mentor and sponsor to others and an example of transformational leadership.

 Dan Smith, Vice President, Enrich Consulting

Daniel Smith leads the consulting practice at Enrich, overseeing customization and implementation of the EAP platform to meet each client's unique needs. Prior to joining Enrich in 2000, he served as a consultant with Applied Decision Analysis and PricewaterhouseCoopers. Dan holds a graduate certificate in engineering management from the University of Cambridge, an MBA from Santa Clara University, and a BSE in mechanical engineering from the University of Pennsylvania. He believes a company runs on its collective stomach, and in his spare time plots reasons to bring cake into the office.

 Richard Sonnenblick, Ph.D., CEO, Enrich Consulting

Richard Sonnenblick founded Enrich Consulting in 1998. His vision has been realized in the Enrich Analytics Platform (EAP), which he created in 2000. Prior to founding Enrich, he built a decision analysis consulting practice at Lumina Decision Systems. Rich holds a PhD and an MS in engineering and public policy from Carnegie Mellon University and a BA in physics from the University of California, Santa Cruz. When Rich isn't running the show at Enrich, he can be found kayaking in Monterey Bay or cruising the singletrack at Wilder Ranch.

Geert Vanhove, Partner, Bluecrux

Geert Vanhove is founding partner at Bluecrux. Bluecrux, founded in 2011, is a team of 60 experts in operations planning. In 2015, bluecrux released Binocs, a resource planning cloud application that targets R&D, Regulatory Affairs and Laboratories. It is trusted by companies such as GSK, Pfizer, UCB and Danone.

Pik Leng Wong, Director, Biologics Project Management Office (PMO), Sanofi

Pik Leng Wong is the Director of PMO for a commercial operation site in Sanofi Genzyme. Armed with an M.S. degree in Chemical Engineering from Northeastern University, she started her career as a Process Engineer in late stage cell culture development and commercial process optimization. She then became a Project Manager in a facility start-up project and later transitioned to operations-type project. She has been in the current PMO role since late 2015.

Yong (Sean) Xue, Ph.D., CFA, Director, Global Portfolio Management, Takeda Pharmaceuticals

Sean is currently the Director, Global Portfolio Management, Takeda Pharmaceuticals. Previously, Sean was the Director, portfolio management, Biomilars at Dr. Reddy’s Laboratories based in NJ, responsible for formulating strategies and plans for developing a portfolio of Biosimilars. Before that, Sean spent many years at Merck &Co. headquarters, first in Business development & licensing and later in strategic portfolio management. Prior to Merck, Sean was a senior Scientist at Thermo Fisher Scientific Corporation, leading research on novel drug target validation technologies. Sean has a MBA from Yale University, a postdoctoral research fellowship from Harvard Medical School, a Ph.D. (Biomedical sciences) from Icahn School of Medicine at Mount Sinai in New York. Sean is also a charter holder of Charter Financial Analyst (CFA).